UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 9, 2014
Aquinox Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
Delaware | 001-36327 | 98-0542593 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
450 887 Great Northern Way,
Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code: (604) 629-9223
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
On December 9, 2014, Aquinox Pharmaceuticals, Inc. (the Company) issued a press release announcing the appointment of Mr. David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits |
Number |
Description | |
99.1 | Press Release of Aquinox Pharmaceuticals, Inc. dated December 9, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Aquinox Pharmaceuticals, Inc. | ||
By: | /s/ Kamran Alam | |
Name: | Kamran Alam | |
Title: | Chief Financial Officer |
Date: December 9, 2014
INDEX TO EXHIBITS
Number |
Description | |
99.1 | Press Release of Aquinox Pharmaceuticals, Inc. dated December 9, 2014 |
Exhibit 99.1
Aquinox Pharmaceuticals Announces Appointment of Mr. David C. Mitchell as Vice President, Global Regulatory Affairs & Quality Assurance.
VANCOUVER, British Columbia December 9, 2014 Aquinox Pharmaceuticals, Inc. (Aquinox) (Nasdaq: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the appointment of Mr. David C. Mitchell as Vice President of Global Regulatory Affairs & Quality Assurance. Mr. Mitchell will join Aquinoxs management team to guide the strategic direction of Aquinoxs global regulatory and quality assurance functions.
Mr. Mitchell has over 35 years of regulatory experience, including negotiations with United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to facilitate new drug approval. Most recently he led global regulatory strategy at AbbVie, Inc. for developmental drug candidates targeting various cancers and immunologic disorders. Mr. Mitchell brings valuable experience from several leading pharmaceutical and biotechnology companies including Biogen Idec, Inc. and Bayer Schering Pharma AG. Mr. Mitchell also serves on the Food and Drug Law Institute (FDLI) Global Committee providing advice on program and policy development in global food and drug law.
We are delighted to welcome David to the Aquinox team, said David Main, Aquinoxs President and CEO. Davids strong background in regulatory leadership, providing guidance to product teams and liaising with regulatory bodies will be integral to Aquinoxs success going forward. With AQX-1125 in two Phase 2 clinical trials nearing completion and two more in preparation, this is the right time to bring on additional regulatory expertise.
About AQX-1125
AQX-1125 is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. By increasing SHIP1 activity, AQX-1125 accelerates a natural mechanism that has evolved to maintain homeostasis of the immune system and reduce immune cell activation and migration. AQX-1125 is Aquinoxs lead product candidate and has demonstrated favorable efficacy, safety and pharmacokinetic properties in preclinical studies and in two proof-of-concept trials examining AQX-1125s effect on healthy individuals with simulated chronic obstructive pulmonary disease (COPD) and, separately, in patients with mild allergic asthma. Aquinox is currently exploring AQX-1125 as a once daily oral treatment in multiple Phase 2 trials.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinoxs lead clinical candidate, AQX-1125, is a small molecule activator of SHIP1 potentially suitable for oral once daily dosing. Aquinox has successfully completed one three-part Phase 1 and two Phase 2a clinical trials with AQX-1125 and is advancing through Phase 2 development. The company has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Cautionary Note on Forward-looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to: the success and timing of our Phase 2 clinical trials; the outcome of our interactions with the FDA and other regulatory authorities; and potential market opportunities for AQXP-1125. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for AQX-1125 or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of AQX-1125 or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of AQX-1125 or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Brendan Payne,
Senior Manager, Investor Relations
604-629-9223
bpayne@aqxpharma.com
MEDIA & PUBLIC RELATIONS CONTACT:
Bianca Nery
MacDougall Biomedical Communications
650-339-7533
aquinox@macbiocom.com